| Followers | 238 |
| Posts | 15504 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Sunday, May 03, 2020 6:48:05 PM
If you click to this link, you'll see that in the last line beginning with "Class D-1 Warrants" at $0.22, that they number 29,411,760. Under the footnote (4), it reads:
Then in the Friday night Form 4, the same number of warrants - 29,411,760 @ $0.22 - were what were extended.
https://www.sec.gov/Archives/edgar/data/1072379/000110465920055770/xslF345X03/tm2018427d1_4.xml
What I'm wondering is what exactly was meant by the "other warrants" held by LP that are also being suspended. Why didn't that receive further definition as to what number those were? I'm hoping and thinking that the 10Q will give more clarity on what was meant.
4. A $5 million portion of a larger pre-existing debt owed by a third party to the reporting person was paid by assignment of this Series A Preferred Stock and Class D-1 Warrants to the reporting person as the third party was unable to make any repayment in cash.
https://www.sec.gov/Archives/edgar/data/1072379/000114420418014763/xslF345X03/tv488530_4.xml
Then in the Friday night Form 4, the same number of warrants - 29,411,760 @ $0.22 - were what were extended.
https://www.sec.gov/Archives/edgar/data/1072379/000110465920055770/xslF345X03/tm2018427d1_4.xml
What I'm wondering is what exactly was meant by the "other warrants" held by LP that are also being suspended. Why didn't that receive further definition as to what number those were? I'm hoping and thinking that the 10Q will give more clarity on what was meant.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
